Skip to main content
. 2018 Oct 24;40(1):561–576. doi: 10.1080/0886022X.2018.1496931

Table 8.

Results from meta-analyses based on genotype counts.

Diseased controls versus cases
Gene Variant RS Studies (n) Cases/Controls (n) RE ORG 95% LL 95% UL I2(%) PQ PE
SLC2A1 XbaI(+)>XbaI(−) rs841853 9 1311/1226 1.26 0.98 1.61 62.31 0.01 0.04
SLC2A1 All in HWE   6 811/735 1.43 1.09 1.88 50.90 0.07 0.08
Subgroup analyses                    
T1DM XbaI(+)>XbaI(−) rs841853 3 494/443 1.49 1.00 2.23 62.13 0.07 0.16
T2DM XbaI(+)>XbaI(−) rs841853 6 817/783 1.14 0.84 1.57 60.86 0.03 0.05
Caucasians XbaI(+)>XbaI(−) rs841853 7 1121/908 1.19 0.91 1.56 62.17 0.01 0.12
Non-Caucasians XbaI(+)>XbaI(−) rs841853 2 190/318 1.71 0.69 4.27 76.70 0.04 na
Sensitivity analysis                    
Excluding current case-control XbaI(+)>XbaI(−) rs841853 8 1118/1078 1.29 0.97 1.72 67.020 0 0.05
  All in HWE   5 618/587 1.54 1.09 2.16 57.70 0.05 0.13
                     
SLC2A1 HaeIII SNP rs1385129 4 716/899 0.74 0.350 1.57 92.05 0 0.18
  All in HWE   3 590/749 1.14 0.73 1.76 74.96 0.02 0.11
                     
SLC2A1 Enh2 SNP1 G>A rs841847 4 783/904 1.48 0.85 2.60 89.27 0 0.13
SLC2A1 All in HWE   4              
Subgroup analyses                    
T1DM Enh2 SNP1 G>A rs841847 2 465/479 1.10 0.87 1.40 0 0.92 na
T2DM Enh2 SNP1 G>A rs841847 2 318/425 2.02 0.58 7.00 94.83 0 na
Caucasians Enh2 SNP1 G>A rs841847 2 454/382 1.08 0.85 1.39 0 0.96 na
Non-Caucasians Enh2 SNP1 G>A rs841847 2 329/522 2.06 0.62 6.86 94.81 0 na
Sensitivity analysis                    
Excluding current case-control Enh2 SNP1 G>A rs841847 3 591/752 1.65 0.78 3.51 92.21 0 0.16
  All in HWE   3              
                     
SLC2A1 Enh2 SNP2 C>T rs841848 3 588/750 1.18 0.95 1.45 0 0.62 0.35
  All in HWE   3              
Subgroup analyses                    
T1DM Enh2 SNP2 C>T rs841848 2 462/477 1.14 0.88 1.48 0 0.37 na
T2DM Enh2 SNP2 C>T rs841848 1 na na na na na na na
Caucasians Enh2 SNP2 C>T rs841848 2 462/477 1.14 0.88 1.48 0 0.37 na
Non-Caucasians Enh2 SNP2 C>T rs841848 1 na na na na na na na
Sensitivity analysis                    
Excluding current case-control Enh2 SNP2 C>T rs841848 na na na na na na na na
                     
SLC2A1 HpyCH4V rs710218 2 257/380 3.87 0.61 24.38 96.94 0.00 na
  All in HWE   2              
Healthy controls versus diseased controls versus cases
SLC2A1 XbaI(+)>XbaI(−) rs841853 6 761/554/845 1.36 0.98 1.89 84.03 0 0.10
SLC2A1 All in HWE   6              
Subgroup analyses                    
T1DM XbaI(+)>XbaI(−) rs841853 1 na na na na na na na
T2DM XbaI(+)>XbaI(−) rs841853 5 691/510/741 1.36 0.92 2.00 87.14 0 0.17
Caucasians XbaI(+)>XbaI(−) rs841853 5 697/509/721 1.17 0.91 1.51 69.98 0.01 0.21
Non-Caucasians XbaI(+)>XbaI(−) rs841853 1 na na na na na na na
Sensitivity analysis                    
Excluding current case-control XbaI(+)>XbaI(−) rs841853 5 568/406/604 1.34 0.88 2.04 86.30 0 0.07
  All in HWE   5              
Healthy controls versus cases
SLC2A1 XbaI(+)>XbaI(−) rs841853 6 761/845 1.58 1.01 2.48 83.03 0 0.23
  All in HWE   6              
Subgroup analyses                    
T1DM XbaI(+)>XbaI(−) rs841853 1 na na na na na na na
T2DM XbaI(+)>XbaI(−) rs841853 5 691/741 1.56 0.92 2.65 86.15 0 0.28
Caucasians XbaI(+)>XbaI(−) rs841853 5 697/721 1.29 0.92 1.81 66.67 0.02 0.42
Non-Caucasians XbaI(+)>XbaI(−) rs841853 1 na na na na na na na
Sensitivity Analysis XbaI(+)>XbaI(−) rs841853 5 568/604 1.568 0.875 2.81 85.765 0 0.15
Excluding current case-control All in HWE   5              

na: non-applicable.